Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer

Boris Guiu, Julie Vincent, Séverine Guiu, Sylvain Ladoire, Pablo Ortega-Deballon, Jean-Pierre Cercueil, Bruno Chauffert, François Ghiringhelli

Abstract
Hepatic arterial infusion (HAI) of chemotherapy can be performed in cases of liver-confined metastatic disease, resulting in increased local drug concentrations. Here we report the case of a 61-year-old man who presented with an isolated large unresectable liver metastasis of colon cancer after failure of surgery and multiple administration of systemic chemotherapy. The patient was treated with a combination of gemcitabine and oxaliplatin using HAI. The tolerance was excellent and a radiological complete response was obtained after 8 cycles of HAI. The rationale for the use of gemcitabine and oxaliplatin as well as that for the combination of the 2 drugs is discussed in this paper. HAI of gemcitabine-oxaliplatin should be evaluated in further clinical trials.

© 2010 Baishideng. All rights reserved.

Key words: Hepatic artery; Chemotherapy; Colon cancer; Liver metastasis; Gemcitabine; Oxaliplatin; Contrast media; Computed tomography

INTRODUCTION
Hepatic arterial infusion (HAI) of chemotherapy is a treatment option in cases of liver-confined metastatic disease from colorectal carcinoma and results in increased local drug concentrations. Although a recent meta-analysis involving 1277 patients reported no significant survival benefit of fluoropyrimidine-based HAI in patients with liver metastases from colorectal cancer, the study suggested using novel anticancer agents and/or drug combinations to improve the efficacy of HAI in the future. There is growing evidence for using the combination of gemcitabine and oxaliplatin in different types of malignancies including colorectal cancer.

Here we present a case of radiological complete response after HAI of gemcitabine-oxaliplatin for a large unresectable liver metastasis from a colon cancer.
CASE REPORT

In April 2005, a 61-year-old man was referred to our hospital with rectal bleeding. A coloscopy revealed a sub-occlusive sigmoid mass 26 cm from the anal margin. A computed tomography (CT) scan performed before surgery revealed one liver metastasis that involved hepatic segment VII. Carcinoembryonic antigen was not a tumor marker for this patient. The patient underwent sigmoid resection. Pathological examination revealed a sigmoid adenocarcinoma with 7 metastatic regional lymph nodes (pT3 pN2 M1). The patient received 10 cycles of the FOLFOX regimen (fluorouracil + oxaliplatin). The disease was stabilized according to RECIST (Response Evaluation Criteria in Solid Tumours). The patient then underwent segmentectomy of hepatic segment VIII in November 2005. In January 2007, the patient presented with 5 new liver metastases that involved hepatic segments IV and VII. The patient received 12 cycles of the FOLFIRI (fluorouracil + irinotecan) and bevacizumab regimen. A partial response was obtained according to RECIST though the 5 metastases were still present on magnetic resonance imaging (MRI). The patient underwent right hepatectomy with partial resection of hepatic segment IV. This resection was complicated by serious liver failure, from which the patient eventually recovered.

In June 2008, the patient presented with a new liver metastasis measuring 4 cm in diameter. Molecular analysis of the tumor revealed no K-Ras mutation and no B-Raf mutation. The patient was treated with 6 cycles of FOLFIRI + cetuximab. However, in October 2008 the metastasis had progressed and measured 5 cm on the liver MRI (Figure 1). A repeat hepatic resection was contraindicated given the history of serious liver failure and the close proximity of the metastasis to the left portal vein. Therefore, HAI was proposed.

An intrahepatic arterial catheter was percutaneously implanted after hepatic arteriography performed by femoral puncture. The catheter was then connected to a subcutaneous implantable port system, located in the inguinal area. After implantation, CT arteriography and a dynamic contrast-enhanced CT (DCE-CT) scan with injection of 1 mL/s of iodine contrast material (350 mg/mL) through the port were performed to check the absence of misperfusion and to assess tumor perfusion before starting hepatic arterial chemotherapy (Figure 2).

The patient received 2 cycles of gemcitabine and oxaliplatin (1 h infusion of gemcitabine 1000 mg/m² followed by 1 h infusion of oxaliplatin 100 mg/m²) every 2 wk. Evaluation by CT arteriography and DCE-CT scan (Figure 2) showed a stable disease according to RECIST, but a dramatic decrease in tumor perfusion. Therefore, the patient received 4 additional cycles. Imaging examinations revealed a partial response (residual tumor diameter: 2.5 cm) as well as an almost complete disappearance of tumor vascularity (Figure 2). After 2 more cycles of arterial chemotherapy, a liver MRI (Figure 3) showed the absence of tumor hyperintensity on diffusion-weighted imaging and a complete response regarding tumor perfusion. Positron emission tomography-CT with no significant hepatic uptake of 18F-fluorodeoxyglucose confirmed the absence of a viable macroscopic tumor. Finally, the treatment was completed with radiofrequency ablation of the residual mass. Only mild toxicity was observed, with grade 2 thrombocytopenia and asthenia with no specific toxicity related to the intraarterial procedure. To date, the patient is still in complete remission.

DISCUSSION

HAI of chemotherapy was first described in the early 1960s[2] and can be proposed in cases of liver-confined metastatic disease. It results in increased local drug concentrations and lower systemic concentrations and hence less toxicity than intravenous administration, provided that the drug is eliminated by hepatic extraction[3]. The use of HAI is also supported by the fact that, once hepatic metastases grow above 2-3 mm in size, they derive their blood supply from the hepatic artery, while normal hepatocytes are perfused mostly from portal circulation[4]. Although a recent meta-analysis involving 1277 patients[5] reported no significant survival benefit of fluoropyrimidine-based HAI in patients with liver metastases of colorectal cancer, the 5-year survival rate of HAI-treated patients is comparable with that of systemic chemotherapy. An important advantage of HAI is that the tumor is preferentially perfused, and there is a lower rate of resistance to chemotherapy because the drug can accumulate in the tumor, especially with fluoropyrimidines. However, the lack of systemic exposure is a constraint, and it is necessary to use a cytotoxic agent that can overcome this limitation. Currently, oxaliplatin is a preferred drug for this purpose, and it is used in combination with other cytotoxic agents or targeted agents.

![Figure 1](image1.png)

**Figure 1** Magnetic resonance imaging (MRI) of the liver before starting hepatic arterial infusion (HAI). A: The hyperintensity of the solitary large (5 cm) metastasis in segment 4 (arrow) on the axial diffusion-weighted image is consistent with malignancy; B: The metastasis is hypervascular (arrow) on the arterial phase after injection of gadolinium chelate.
metastases from colorectal cancer, the study suggested using novel anticancer agents and/or drug combinations to improve the efficacy of HAI in the future. One of the major drawbacks of fluoropyrimidine-based HAI is the prolonged infusion time, which, in addition to causing patient discomfort, is likely to be responsible for chronic hepatobiliary toxicity. To our knowledge, this is the first case to report the combined use of gemcitabine and oxaliplatin for HAI. The addition of oxaliplatin in systemic chemotherapy for metastatic colorectal cancer has resulted in a higher response rate and longer survival than with 5-fluorouracil and leucovorin. HAI of oxaliplatin in a rabbit VX2 tumor model showed that the drug accumulated in the liver metastases in a 4:3 ratio (tumor/normal liver), thereby explaining its low systemic bioavailability and thus, the good tolerance. Human phase I or I/II studies reported a dose-limiting toxicity between 150 mg/m² and 175 mg/m² of oxaliplatin for every 3-wk administration via HAI. The 100 mg/m² dose used in our patient was well tolerated and resulted in no specific toxicity. However, since firstly oxaliplatin as a single agent has demonstrated only moderate activity in patients with metastatic colorectal cancer and secondly, its combination with fluoropyrimidines would necessitate prolonged infusion with subsequent hepatobiliary toxicity, we needed to use a combination of oxaliplatin with another chemotherapeutic agent.

Gemcitabine is a deoxycytidine analogue which has to be intracellularly phosphorylated to its active forms (gemcitabine diphosphate and triphosphate) by deoxycytidine kinase, increased levels of which are found in liver metastases compared to normal liver tissue. In addition, an in vitro study showed that gemcitabine had concentration- and time-dependent cytotoxic effects on many colon cancer cell lines. As HAI makes it possible to reach an effective concentration locally, gemcitabine was deemed suitable for HAI. Interestingly, an experimental study conducted by Faivre et al. showed, in human colon cancer cell lines, a supra-additive effect of gemcitabine in combination with oxaliplatin, as well as a stronger effect of gemcitabine followed by oxaliplatin than the inverse. In a phase I study by Vogl et al., a maximum-tolerated dose of 1400 mg/m² gemcitabine was reached after weekly 20-min HAIs of the drug in patients with cholangiocarcinomas and liver metastases from pancreatic cancer. A recent phase I study reported that gemcitabine given at doses higher or longer than

---

Figure 2  Computed tomography (CT) of liver metastasis. A: CT arteriography at baseline (A1), after 2 cycles (A2) and after 6 cycles (A3) of HAI. The metastasis was hypervascular at baseline. It became shorter after 2 cycles but remained as a stable disease according to RECIST. After 6 cycles, a partial response was observed (43% reduction in diameter); B: Dynamic contrast-enhanced CT (DCE-CT) scan at baseline (B1), after 2 cycles (B2) and after 6 cycles (B3). At baseline, the tumor was progressively and massively enhanced. After 2 cycles, there was a dramatic decrease in tumor perfusion, strongly suggesting the efficacy of HAI. Normal hepatic segment 4 is strongly enhanced. After 6 cycles, only small enhanced areas are visible within the residual tumor.
the recommended systemic dose of 1000 mg/m$^2$ over 30 min was well tolerated. All these results are consistent with the excellent tolerance in our patient.

CT arteriography using the implantable port system is useful to detect misperfusion[18] which may be responsible for undertreatment of liver metastases and/or for inadvertent chemotherapy perfusion of extra-hepatic organs such as the gastroduodenal wall. Early endovascular management prevents gastroduodenal lesions caused by the toxicity of chemotherapeutic drugs and allows treatment by HAI to be continued[19]. In this case, visual assessment of tumor perfusion on DCE-CT helped us to detect an early response to HAI. Although optimum quantitative perfusion parameters have not yet been determined, visual analysis of DCE-CT may be useful for monitoring the effects of HAI over time.

In conclusion, despite the poor prognosis of colon cancer with synchronous liver metastases, this patient has survived for 52 mo and is to date disease-free. This suggests that further trials involving HAI of oxaliplatin and gemcitabine in metastatic colon cancer are required.

REFERENCES

1 Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007; 25: 5649-5654

2 Clarkson B, Young C, Dierick W, Kuehn P, Kim M, Berrett A, Clapp P, Lawrence W Jr. Effects of continuous hepatic artery infusion of antimitotabolites on primary and metastatic cancer of the liver. Cancer 1962; 15: 472-488

3 van Riel JM, Peters CJ, Mammatas LH, Honeywell RJ, Laan AC, Ruyster R, van den Berg FG, Giaccone G, van Groeningen CJ. A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. Eur J Cancer 2009; 45: 2519-2527

4 Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30: 969-977

5 Druceux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboisin M. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005; 23: 4881-4887

6 de Gramont A, Figer A, Seymour M, Homerin M, Hnissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Ball N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2008; 26: 2988-2997

7 Dzodici R, Gomez-Abuin G, Rougier P, Bonnay M, Ardoin P, Goyette A, Rixe O, Druceux M, Munck JN. Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs 2004; 15: 647-650

8 Guthoff R, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrson H, Kornmann M. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res 2003; 23: 5203-5208

9 Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, Dromain C, Pocard M, Ducruet M. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008; 15: 219-226

10 Fiorentini G, Rossi S, Dentico P, Meucci F, Bonechi F, Bernadeschi P, Cantore M, Guadagni S, De Simone M. Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase I-II clinical study. Anticancer Res 2004; 24: 2093-2096

11 Kern W, Beckert B, Lang N, Stemmler J, Beykirch M, Stein J, Goecke E, Waggasserhauser T, Braess J, Schalhorn A, Hiddemann W. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol 2001; 12: 599-603

12 Diaz-Rubio E, Lasarte J, Zanioboni A, Labranca R, Cortes-Funes H, de Braud F, Boni C, Benavides M, Dallavalle G, Homerin M. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998; 9: 105-108

13 Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23: 3-15

14 van der Wilt CL, Kroep JR, Loves WJ, Rots MG, van Groeningen CJ, Kaspers GJ, Peters GJ. Expression of deoxycytidine kinase in leukemic cells compared with solid tumour cell lines, liver metastases and normal liver. Eur J Cancer 2003; 39: 691-697

15 Kornmann M, Butzer U, Blatter J, Beger HG, Link KH. Preclinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer. Eur J Surg Oncol 2000; 26: 583-587

16 Faireve S, Raymond E, Woynarowski JM, Citvokovic E. Supra-additive effect of 2,2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44: 117-123

Figure 3 MRI of the liver after 8 cycles of HAI. A: The lesion is isointense to the liver parenchyma on the diffusion-weighted image thereby suggesting the absence of viable tumor. B: The lesion is completely avascular (arrow) during the arterial phase after injection of gadolinium chelate. Note the enhancement of the remnant segment 4.
Guiu B et al. Hepatic arterial infusion of gemcitabine-oxaliplatin

17 Vogl TJ, Schwarz W, Eichler K, Hochmuth K, Hammer-stingl R, Jacob U, Scheller A, Zangos S, Heller M. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol 2006; 132: 745-755

18 Seki H, Kimura M, Kamura T, Miura T, Yoshimura N, Sakai K. Hepatic perfusion abnormalities during treatment with hepatic arterial infusion chemotherapy: value of CT arteriography using an implantable port system. J Comput Assist Tomogr 1996; 20: 343-348

19 Proietti S, De Baere T, Bessoud F, Qanadli SD, Schnyder P, Denys A. Interventional management of gastro-duodenal lesions complicating intra-arterial hepatic chemotherapy. Eur Radiol 2007; 17: 2160-2165

S- Editor Wang YR L- Editor Cant MR E- Editor Zheng XM